{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:53:17Z","timestamp":1783151597543,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40265-018-1005-4","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T11:47:41Z","timestamp":1541677661000},"page":"1741-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dolutegravir\/Rilpivirine: A Review in HIV-1 Infection"],"prefix":"10.1007","volume":"78","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"issue":"3","key":"1005_CR1","first-page":"e515","volume":"8","author":"AB Bhatti","year":"2016","unstructured":"Bhatti AB, Usman M, Kandi V. Current scenario of HIV\/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus. 2016;8(3):e515.","journal-title":"Cureus"},{"key":"1005_CR2","unstructured":"European AIDS Clinical Society. Guidelines version 9.0; 2017. http:\/\/eacsociety.org. Accessed 29 Oct 2018."},{"key":"1005_CR3","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. https:\/\/adisinfo.nih.gov\/guidelines. Accessed 29 Oct 2018."},{"issue":"7","key":"1005_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/1060028018758432","volume":"52","author":"R Boswell","year":"2018","unstructured":"Boswell R, Foisy MM, Hughes CA. Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review. Ann Pharmacother. 2018;52(7):681\u20139.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1005_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11904-018-0371-6","volume":"15","author":"Buckley R de Miguel","year":"2018","unstructured":"de Miguel Buckley R, Montejano R, Stella-Ascariz N, et al. New strategies of ARV: the road to simplification. Curr HIV\/AIDS Rep. 2018;15(1):11\u20139.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"1005_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/14740338.2017.1343300","volume":"16","author":"V Soriano","year":"2017","unstructured":"Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017;16(8):923\u201332.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1005_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14656566.2018.1450866","volume":"19","author":"MR Caplan","year":"2018","unstructured":"Caplan MR, Daar ES, Corado KC. Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opin Pharmacother. 2018;19(6):589\u201396.","journal-title":"Expert Opin Pharmacother"},{"key":"1005_CR8","unstructured":"European Medicines Agency. Juluca 50\u00a0mg\/25\u00a0mg film-coated tablets: EU summary of product characteristics; 2018. http:\/\/www.ema.europa.eu. Accessed 29 Oct 2018."},{"key":"1005_CR9","unstructured":"ViiV Healthcare. JULUCA (dolutegravir and rilpivirine) tablets, for oral use: US prescribing information; 2017. https:\/\/www.fda.gov. Accessed 29 Oct 2018."},{"issue":"2","key":"1005_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1005_CR11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","volume":"74","author":"PL McCormack","year":"2014","unstructured":"McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74(11):1241\u201352.","journal-title":"Drugs"},{"issue":"10123","key":"1005_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"JM Llibre","year":"2018","unstructured":"Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839\u201349.","journal-title":"Lancet"},{"issue":"9","key":"1005_CR13","doi-asserted-by":"publisher","first-page":"e00748-18","DOI":"10.1128\/AAC.00748-18","volume":"62","author":"R Mehta","year":"2018","unstructured":"Mehta R, Wolstenholme A, Di Lullo K, et al. Bioequivalence of a fixed-dose combination tablet of the complete 2-drug regimen dolutegravir and rilpivirine for the treatment of HIV-1 infection. Antimicrob Agents Chemother. 2018;62(9):e00748-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1005_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy426","author":"ER Elliot","year":"2018","unstructured":"Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition. Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/ciy426.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"1005_CR15","first-page":"S28","volume":"19","author":"C Orkin","year":"2018","unstructured":"Orkin C, Khuong-Josses MA, Lutz T, et al. Safety and efficacy of DTG + RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location [abstract no. P22]. HIV Med. 2018;19(Suppl 2):S28\u20139.","journal-title":"HIV Med"},{"key":"1005_CR16","doi-asserted-by":"crossref","unstructured":"Walmsley S, Richmond GJ, Bredeek F, et al. SWORD-1 and SWORD-2: subgroup analysis of 48-week results by age, race and gender [abstract no. 1382 plus poster]. In: IDWeek; 2017.","DOI":"10.1093\/ofid\/ofx163.1078"},{"key":"1005_CR17","unstructured":"Oglesby A, Punekar Y, Angelis K, et al. Patient reported outcomes after switching to a 2-drug regimen of dolutegravir + rilpivirine: results from the SWORD-1 and SWORD-2 studies [abstract no. BPD1\/2 plus poster]. In: 16th European AIDS conference; 2017."},{"key":"1005_CR18","unstructured":"Aboud M, Orkin C, Podzamczer D, et al. Durable suppression 2 years after switch to DTG+RPV 2-drug regimen: SWORD 1 and 2 studies [abstract no. THPEB047]. In: 22nd international AIDS conference; 2018."},{"issue":"1","key":"1005_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1060028017728294","volume":"52","author":"JL Revuelta-Herrero","year":"2018","unstructured":"Revuelta-Herrero JL, Chamorro-de-Vega E, Rodriguez-Gonzalez CG, et al. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52(1):11\u20138.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1005_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/1060028018761600","volume":"52","author":"AF Capetti","year":"2018","unstructured":"Capetti AF, Cossu MV, Sterrantino G, et al. Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data. Ann Pharmacother. 2018;52(8):740\u20136.","journal-title":"Ann Pharmacother"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2325958218760847","volume":"17","author":"R Palacios","year":"2018","unstructured":"Palacios R, Mayorga M, Gonzalez-Domenech CM, et al. Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care. 2018;17:1\u20134.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"9","key":"1005_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/hiv.12506","volume":"18","author":"P Gantner","year":"2017","unstructured":"Gantner P, Cuzin L, Allavena C, et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017;18(9):704\u20138.","journal-title":"HIV Med"},{"key":"1005_CR23","unstructured":"Diaz A, Casado JL, Dronda F, et al. Dolutegravir plus rilpivirine in suppressed heavily pre-treated HIV-infected patients [abstract no. TUPDB0106 plus poster]. In: 21st international AIDS conference; 2016."},{"issue":"Suppl 2","key":"1005_CR24","first-page":"S17","volume":"19","author":"C Orkin","year":"2018","unstructured":"Orkin C, Llibre J, Kahl L, et al. Renal, inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies [abstract no. O37 plus oral presentation]. HIV Med. 2018;19(Suppl 2):S17.","journal-title":"HIV Med"},{"key":"1005_CR25","unstructured":"US FDA. FDA drug safety communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq); 2018. https:\/\/www.fda.gov. Accessed 29 Oct 2018."},{"issue":"4","key":"1005_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0000000000001725","volume":"32","author":"GA McComsey","year":"2018","unstructured":"McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32(4):477\u201385.","journal-title":"AIDS"},{"issue":"3","key":"1005_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.18683\/germs.2017.1115","volume":"7","author":"D Back","year":"2017","unstructured":"Back D. 2-drug regimens in HIV treatment: pharmacological considerations. Germs. 2017;7(3):113\u20134.","journal-title":"Germs"},{"issue":"10123","key":"1005_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(18)30008-4","volume":"391","author":"MA Boyd","year":"2018","unstructured":"Boyd MA, Cooper DA. Combination ART: are two drugs as good as three? Lancet. 2018;391(10123):817\u20139.","journal-title":"Lancet"},{"issue":"1","key":"1005_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1185\/03007995.2013.844685","volume":"30","author":"I Aldir","year":"2014","unstructured":"Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014;30(1):89\u201397.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"1005_CR30","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jval.2018.04.044","volume":"21","author":"E Arthurs","year":"2018","unstructured":"Arthurs E, Ward T, Darlington O, et al. Dolutegravir and rilpivirine to treat virologically suppressed adults living with HIV-1: a Canadian cost-utility analysis. Value Health. 2018;21(Suppl 1):S9\u201310.","journal-title":"Value Health"},{"issue":"1","key":"1005_CR31","doi-asserted-by":"publisher","first-page":"e0147821","DOI":"10.1371\/journal.pone.0147821","volume":"11","author":"DE Sweet","year":"2016","unstructured":"Sweet DE, Altice FL, Cohen CJ, et al. Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States. PLoS One. 2016;11(1):e0147821.","journal-title":"PLoS One"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-1005-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:50:10Z","timestamp":1659113410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-1005-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1005-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"8 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}